Each enteric coated tablet contains: Serratiopeptidase 10 mg (20,000 Serratiopeptidase units).
Excipients/Inactive Ingredients: Lactose monohydrate, maize starch, light magnesium carbonate, sodium starch glycolate, magnesium stearate, opadry white (YS-1-7027), opadry enteric white (OY-P-7171), isopropyl alcohol, dichloromethane and purified water.
Pharmacotherapeutic group: Enzymes, other drugs for disorders of the musculo-skeletal system. ATC code: M09AB.
Pharmacology: Pharmacodynamics: Serratiopeptidase acts as a fibrinolytic, anti-inflammatory, anti-oedematous and inactivates bradykinin. It is able to increase the diffusion of antibiotics and cytostatic agents in tissue.
Pharmacokinetics: There is still no data available on the bioavailability in humans. Animal experimental findings shows that Serratiopeptidase is absorbed from the duodenum. After 10 mg/kg Serratiopeptidase administered intraduodenally to dogs, radioimmunoassay identified peak concentrations in the lymph (26 ng/ml), in the portal vein blood (16 ng/ml) and in arterial blood (about 11 ng/ml), by binding to alpha2-macroglobulin Serratiopeptidase loses its antigenicity; while maintaining a sufficient proteolytic activity.
As an anti-inflammatory therapy in inflammatory swelling and suppuration, in addition to causal - eg antibiotic or surgical - therapy, or when a causal therapy is missing or when it is not applied in individual cases.
Inflammation after surgery or injury.
Inflammation of the following diseases: In otorhinolaryngology: Sinusitis.
In dentistry: Pericoronitis of wisdom teeth or alveolar abscess of other teeth, when a surgical therapy is not possible or advisable.
In gynecology: Breast swelling and discomfort in the early postpartum lactation due to hormone caused galactostasis.
In Urology: In case of cystitis in addition to antibiotic therapy.
Dosage: Unless otherwise prescribed.
Adults: Depending on the severity of the disease swallow 1-2 tablets, 3 times a day without chewing 2 hours after meal.
Children and adolescents (Children ≥ 6 years of age): Depending on the severity of the disease swallow 1 tablet, 2-3 times a day without chewing 2 hours after meal.
Kuserta should not be used (see Contraindications) in infants and young children.
Mode of administration & duration of treatment: Kuserta tablet is swallowed whole after meal. The treatment is usually performed until alleviation of symptoms. Generally, a treatment period of 1-2 weeks is sufficient. The application period should not exceed 3 months.
Intoxications have not occurred even after high doses (till 15 tablets daily for 60 days). If necessary, gastric lavage should be considered.
Hypersensitivity to Serratiopeptidase or any of the excipients.
Gastric ulcers in upper GI tract caused by gastric acid.
This product is not suitable for infants and young children.
If symptoms persist or worsen, discontinue use and consult a health care practitioner.
If the patient is pregnant or breastfeeding, consult a health care practitioner prior to use.
If the patient has a gastrointestinal lesion/ulcer, is taking anticoagulant/blood thinner or anti-inflammatory medication, is having coagulation disorders, liver and kidney damage or is having surgery, consult a health care practitioner prior to use.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take Kuserta.
Effects on Ability to Drive and Use Machines: There have been no studies on the effects on the ability to drive or operate machinery.
Pregnancy: There is no sufficient data to determine the safety of Serratiopeptidase for humans during pregnancy. There are insufficient animal studies regarding the effects of Serratiopeptidase on pregnancy, embryonal/fetal development, birth and postnatal development. Serratiopeptidase may be prescribed during pregnancy only if clearly indicated.
Lactation: It is not known that Serrapeptase, the active ingredient of Kuserta is excreted in human milk. No adverse effects were observed during lactation in children of mothers undergoing treatment with serrapeptase.
In rare cases: Stomach and intestinal discomfort, nausea, vomiting and diarrhea.
In isolated cases: Hypersensitivity reaction, e.g. skin rash, erythema, urticaria, itching, also dyspnoea and edema.
In individual cases: Elevated liver enzymes (SGOT, SGPT, AP, γ-GT), jaundice and hepatitis, severe skin (Stevens-Johnson-Syndrome, Lyell-syndrome) and respiratory disorders (Löffler-Syndrome, Pneumonitis) and shock.
Adverse Drug Reaction: Inform doctors about unexpected reactions after using drugs.
Since the concomitant use of Serratiopeptidase with an anticoagulant may intensify the anticoagulant effect, Serratiopeptidase should be administered with care under close observation.
In a single case, the co-administration of carbamazepine and Serratiopeptidase led to a decrease in blood serum concentration and thus a decreased effect of carbamazepine.
Store below 30°C in dry place. Protect from direct sunlight.
Shelf Life: 36 months.
M09AB - Enzymes ; Used in the treatment of musculo-skeletal disorders.
EC tab 10 mg (white colour, circular shape, biconvex, having plain surface on both sides) x 5 x 30's.
Sign Out
